Corporate Achievements Since 2004

  • In-licensed patented technology from University of New Hampshire for production of hyperpolarized xenon-129
  • Filed Investigational New Drug status with the US FDA for hyperpolarized xenon-129
  • Determined that drug research for regulatory advancement could proceed under FDA safe-harbor
  • Completed Phase I studies of 30 healthy volunteers in 2006, advancing to Phase II
  • Assembled world class development team
  • Scaled up the productive output of hyperpolarized xenon-129 ten-fold
  • Applied new technology to SEOP production of hyperpolarized helium-3, improving production rates ten-fold
  • Raised $7M in non-dilutive capital through competitive research grant proposals
  • Fifth patent awarded strengthens Xemed’s worldwide patent portfolio
  • Secured collaboration with first pharmaceutical partner to evaluate imaging biomarkers for cystic fibrosis severity
  • Established collaboration to evaluate MagniXene®-guided bronchial thermoplasty
  • Expanding MagniXene® Imaging Network by negotiating with six new Centers for temporary and long-term installations of XeBox-E10